Background Trials evaluating implantable hemodynamic monitors to manage patients with
heart failure (HF) have shown reductions in HF hospitalizations but not mortality. Prior meta …

Pulmonary hypertension (PH) is a prevalent disease of the pulmonary vasculature that is
characterised by considerable morbidity and mortality. Substantial efforts have been made …

Beta-blocker (BB) therapy is a main pillar in treating patients with heart failure and reduced
ejection fraction and has shown a prognostic benefit. However, evidence for application of …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition in which an
organic thrombus remains in the pulmonary artery (PA) even after receiving anticoagulation …

Pulmonary arterial hypertension (PAH) is a multifactorial disease associated with the
remodeling of pulmonary blood vessels. If left unaddressed, PAH can lead to right heart …

Pulmonary hypertension (PH) is defined by the presence of a mean pulmonary arterial
pressure> 20 mmHg. Current guidelines describe five groups of PH with shared …

Right‐sided heart failure and tricuspid regurgitation are common and strongly associated
with poor quality of life and an increased risk of heart failure hospitalizations and death …

Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary
vasculature with associated pulmonary and cardiac remodeling. PAH was a uniformly fatal …

Pulmonary arterial hypertension (PAH) is a complex disease of multifactorial origin. While
registries have demonstrated that women are more susceptible to the disease, females with …

Pulmonary arterial hypertension (PAH) is a rare cardiovascular disorder leading to
pulmonary hypertension and, often fatal, right heart failure. Sex differences in PAH are …